A New Hepatitis C Treatment: No Interferon or Ribavirin Required! | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

How Can Chronic Pain Lead to Hepatitis C?

Back to News Homepage
Next

Harvoni Is Here: The Once-a-Day, Single Hep C Pill

A New Hepatitis C Treatment: No Interferon or Ribavirin Required!

The Editors at Hepatitis Central
October 27, 2014

Print this page

The side effects of interferon and ribavirin therapies for the treatment of Hepatitis C can be monstrous: nausea, fatigue, insomnia, diarrhea, depression and itchy skin. Learn about a new treatment – Harvoni –that does not require the use of interferon or ribavirin.
Viekira Pak Effective Without Ribavirin Pin it on Pinterest

Harvoni Takes the Sting Out of Hepatitis C Treatment

For the first time, hepatitis C can be cured without interferon and ribavirin, which can cause fatigue and depression.

Written by David Heitz | October 26, 2014

Finally, there’s a medication to cure hepatitis C that doesn’t require use of the dreaded drugs interferon or ribavirin.

The U.S. Food and Drug Administration earlier this month approved Harvoni, a once-daily tablet manufactured by Gilead Sciences. Harvoni is a combination medication that includes sofosbuvir (Sovaldi), another Gilead breakthrough treatment approved late last year, and ledipasvir, which is also made by Gilead.

Continue reading this entire article:
http://www.healthline.com/health-news/harvoni-takes-sting-out-of-hepatitis-c-treatment-102614

13 Comments
Share
Share
Previous

How Can Chronic Pain Lead to Hepatitis C?

Back to News Homepage
Next

Harvoni Is Here: The Once-a-Day, Single Hep C Pill

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.